|
|
|
Small Stocks, Big Money™
|
|
Weekly Newsletter
|
|
|
|
|
|
|
|
Nova Minerals Hits High-Grade Gold at Wombat Prospect with Exceptional 360 g/t Au Assay
Nova Minerals Limited (Nasdaq: NVA, ASX: NVA) continues to deliver impressive results at its Estelle Gold and Critical Minerals Project in Alaska, reporting new high-grade gold assays from the Wombat Prospect. Highlights include a stunning 360 g/t Au, the second-highest gold sample ever recorded at Estelle, along with significant gallium results reaching 74.5 ppm. These findings expand the mineralized strike length at Wombat to 1km, reinforcing the project's potential. The discovery of gallium, a critical mineral essential to U.S. supply chains, further underscores Estelle's strategic value. Drill testing is on the horizon for this promising early-stage target.
|
|
|
|
Fathom Holdings Expands Innovation with Bitcoin Treasury Strategy and Projects $110M Revenue Boost from Acquisition
Fathom Holdings (Nasdaq: FTHM) announced a bold new treasury strategy, incorporating Bitcoin (BTC) as a key asset, with plans to allocate up to 50% of excess cash toward BTC purchases. This move aligns with Fathom’s commitment to innovation, as the company also prepares to enable Bitcoin payments within its real estate ecosystem. Additionally, the integration of My Home Group, acquired in November 2024, remains on track and is projected to contribute $110 million in revenue for 2025, further strengthening Fathom’s national footprint.
|
|
|
|
|
VSee Health Secures $935K Contracts with Major Medtech Companies, Expanding Role in $800B Industry
VSee Health (Nasdaq: VSEE) announced $935,000 in contracts with leading medical device manufacturers, highlighting the company's growing presence in the medtech sector. VSee’s cutting-edge telehealth platform offers unique solutions like remote operation of medical devices, lossless imaging screen sharing, and Uber-like routing for support, helping medtech companies boost ROI and streamline customer support. With the global medtech market projected to reach $800 billion by 2030, VSee’s scalable, HIPAA-compliant platform positions the company as a critical partner for device manufacturers aiming to enhance efficiency and customer experience.
|
|
|
|
|
|
|
Greenwich LifeSciences Adds Harvard and Johns Hopkins to Phase III FLAMINGO-01 Trial
Greenwich LifeSciences (Nasdaq: GLSI) announced the addition of Harvard University and Johns Hopkins University as clinical sites for its Phase III FLAMINGO-01 trial, which evaluates GLSI-100, an immunotherapy to prevent breast cancer recurrence. Esteemed oncologists Dr. Laura Spring (Harvard) and Dr. Cesar Santa-Maria (Johns Hopkins) join the Steering Committee, bringing expertise in HER2-targeted therapies and breast cancer immunotherapy. FLAMINGO-01 is enrolling high-risk HER2-positive breast cancer patients across a planned 150 global sites, aiming to assess GLSI-100’s safety and efficacy in reducing recurrence risk.
|
|
|
|
|
bioAffinity Technologies Secures Australian Patent for Early-Stage Lung Cancer Diagnostic
bioAffinity Technologies (Nasdaq: BIAF) announced that its patent application for CyPath® Lung, a noninvasive diagnostic test for early-stage lung cancer, has been accepted by the Australian Patent Office. The patent, titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning,” strengthens the company’s global IP portfolio and is set to expire in 2042. CyPath® Lung, leveraging advanced flow cytometry and AI, demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients.
|
|
|
Recent News
|
|
|
Recent Research Coverage Updates
| Company |
Rating |
Price Target |
Firm |
Report Date |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$3 |
ThinkEquity |
January 13, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$27 |
Alliance Global Partners |
January 2, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$18 |
Northland Capital Markets |
January 22, 2025 |
| OS Therapies (NYSE American: OSTX) |
Buy |
$9 |
Brookline |
January 15, 2025 |
| OS Therapies (NYSE American: OSTX) |
Buy |
$15 |
Maxim |
January 15, 2025 |
| OS Therapies (NYSE American: OSTX) |
Buy |
$20 |
D Boral Capital |
January 15, 2025 |
| Venu Holding Corp. (NYSE American: VENU) |
Buy |
$15 |
ThinkEquity |
January 6, 2025 |
| Nova Minerals (NASDAQ: NVA) |
Buy |
$25 |
ThinkEquity |
December 7, 2024 |
| Alliance Entertainment (NASDAQ: AENT) |
Buy |
$8 |
ThinkEquity |
December 16, 2024 |
| Calidi Biotherapeutics (NYSE American: CLDI) |
Buy |
$10 |
Ladenburg Thalmann |
November 21, 2024 |
| ASP Isotopes (Nasdaq: ASPI) |
Buy |
$4.50 |
Cannacord Genuity |
October 4, 2024 |
| LOBO EV (Nasdaq: LOBO) |
Buy |
$5 |
Zacks Small-Cap Research |
May 15, 2024 |
| GreenPower Motor (Nasdaq: GP) |
Buy |
$1.65 |
Roth |
August 15, 2024 |
| Enlivex Therapeutics (Nasdaq: ENLV) |
Buy |
$13 |
EF Hutton |
August 27, 2024 |
| GreenPower Motor (Nasdaq: GP) |
Buy |
$3 |
RF Lafferty |
September 11, 2024 |
| GreenPower Motor (Nasdaq: GP) |
Buy |
$5 |
Maxim |
July 2, 2024 |
| GreenPower Motor (Nasdaq: GP) |
Hold |
n/a |
BTIG |
July 1, 2024 |
| GreenPower Motor (Nasdaq: GP) |
Buy |
$3 |
Roth |
April 1, 2024 |
| BioVie (Nasdaq: BIVI) |
Buy |
$3 |
ThinkEquity |
July 1, 2024 |
| Calidi Biotherapeutics (NYSE American: CLDI) |
Buy |
$1 |
Ladenburg Thalman |
June 27, 2024 |
| Calidi Biotherapeutics (NYSE American: CLDI) |
Buy |
$1 |
Rodman & Renshaw |
June 27, 2024 |
| Calidi Biotherapeutics (NYSE American: CLDI) |
Buy |
$2 |
RW Baird |
May 14, 2024 |
| Unusual Machines (NYSE American: UMAC) |
Buy |
n/a |
ThinkEquity |
June 17, 2024 |
| Soligenix (Nasdaq: SNGX) |
n/a |
$4.15 |
Zacks Research |
June 14, 2024 |
| Enlivex Therapeutics (Nasdaq: ENLV) |
Buy |
$6 |
HC Wainwright |
June 11, 2024 |
| Sixty Degrees Pharma (Nasdaq: SXTP) |
Hold |
n/a |
HC Wainwright |
June 6, 2024 |
| Sixty Degrees Pharma (Nasdaq: SXTP) |
Buy |
n/a |
Ascendiant |
May 21, 2024 |
| American Resources (Nasdaq: AREC) |
Buy |
n/a |
HC Wainwright |
June 3, 2024 |
|
|
|
|
|
Small Stocks, Big Money™ Podcast
The podcast features in-depth interviews with CEO’s from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
Available on:
|
|
|
|
Upcoming Events
|
|
|
NASDAQ: ASPI - ASP Isotopes
4:15pm Eastern
This exclusive event will provide investors with an opportunity to gain critical insights into ASP Isotopes' strategic initiatives and technological advancements.
|
|
|
|
NYSE American: CLDI - Calidi Biotherapeutics
4:15pm Eastern
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.
|
|
|
|
Archived Events
|
|
|
NASDAQ: NXL - Nexalin Technology
4:15pm Eastern
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic.
|
|
|
|
Quote of the Week
|
"We've found that the area that we can perform the best is in the microcap space. So it's a microcap value bent that really differentiates us, and that is because it's an area of the market where there are enormous inefficiencies and where our hard work pays off, because we can identify opportunities that are significantly underpriced."
|
|
|
— Eric Kuby, CIO of North Star Investment Management
|
|
|
|
|
RedChip TV
|
|
|
|
RedChip Highlights GreenPower Motor Company (NASDAQ: GP) & Nova Minerals Limited (NASDAQ: NVA)
|
|
|
|
|
|
|
Order "Small Stocks, Big Money™ Today!
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
|
|
|
|
|
|
|
Lesson of the Week
One of the hardest decisions small-cap investors face is knowing when and why to sell a stock.
|
|
|
|
|
|
|
